| Alternative title | Primary standardization and half-life determination of 225 Ac at NRC |
|---|
| Download | - Will be available here on November 8, 2025
|
|---|
| DOI | Resolve DOI: https://doi.org/10.1016/j.apradiso.2023.111105 |
|---|
| Author | Search for: Galea, R.1ORCID identifier: https://orcid.org/0000-0003-1639-3788; Search for: Moore, K.1 |
|---|
| Affiliation | - National Research Council of Canada. Metrology Research Centre
|
|---|
| Funder | Search for: Canadian Nuclear Laboratories |
|---|
| Format | Text, Article |
|---|
| Subject | ²²⁵Ac; targeted alpha therapy; half-life |
|---|
| Abstract | A solution of ²²⁵ Ac was standardized by NRC using the triple-to-double coincidence ratio (TDCR) method. The counting efficiencies were calculated assuming a counting efficiency of 100% for alpha decays and those calculated using the MICELLE2 Monte Carlo code for beta decays and was approximately 500% for the NRC TDCR system. The relative uncertainty for the activity concentration was determined to be 0.25%. This agreed with measurements performed using gamma spectroscopy and a predicted calibration factor for the Vinten 671 ionization chamber as calculated using an EGSnrc model, implementing radioactive decay. Finally, the half-life of ²²⁵ Ac was determined from long-term measurements using ionization chambers and liquid scintillation counting. The NRC measured half-life for ²²⁵ Ac was found to be 9.914(4) days and is consistent within an expanded uncertainty coverage of k = 2 with the most recent (Kossert et al., 2020; Pommé et al., 2012) measurements of this decay parameter. |
|---|
| Publication date | 2023-11-08 |
|---|
| Publisher | Elsevier |
|---|
| In | |
|---|
| Language | English |
|---|
| Peer reviewed | Yes |
|---|
| Export citation | Export as RIS |
|---|
| Report a correction | Report a correction (opens in a new tab) |
|---|
| Record identifier | 9aa29a95-2011-4861-a3d9-706cc9649d1f |
|---|
| Record created | 2024-01-08 |
|---|
| Record modified | 2024-01-10 |
|---|
